Eric Cantor Named CEO of PhRMA Amid Merck Dividend Sustainability Questions

Eric Cantor has been appointed as the new CEO and president of PhRMA, taking over from Steven Ubl on November 9. Cantor's background as House Majority Leader from 2011 to 2014 and his experience in global business are expected to enhance PhRMA's ability to navigate regulatory and policy challenges.

MERCK, a leading global healthcare company with a market capitalization of $362.18 billion, operates primarily in the healthcare sector under the drug manufacturers industry. Merck currently offers a dividend yield of 2.38%, which is modest but attractive for income-focused investors in the healthcare sector.

However, the dividend payout ratio of 1.11 is notably high, indicating that Merck is paying out more in dividends than it earns in net income, raising concerns about the sustainability of its dividend over the long term. The stock is currently modestly overvalued by 21.5% relative to its GF Value™ of $120.87.